Introduction {#s1}
============

Chronic heart failure (CHF), a clinical syndrome that results from various cardiovascular diseases, represents one of the largest contributors to healthcare burden and mortality worldwide and remains a worsening global problem especially in aging populations ([@B28]). As a heterogeneous entity, recent advances of heart failure (HF) treatment can slow down its progression to some extent. In-depth understanding of novel pathological mechanisms is essential to develop effective therapy and assessment of HF prognosis in individual patients.

In response to various stress, compensatory cardiac remodeling characterized by progressive cardiac hypertrophy and fibrosis occurred and ultimately lead to cardiac dysfunction known as HF. The etiology of CHF has commonly been categorized into ischemic cardiomyopathy (ICM) and non-ICM, distinguished by the presence or absence of significant coronary artery disease ([@B9]). In addition, these two categories have distinct long-term prognosis ([@B9]) and different responses to treatment ([@B11]). Recent advances in the treatment and diagnosis of myocardial infarction (MI) have improved the life quality for MI patients, however, its mortality is still high since the occurring of severe complications, especially ventricular fibrillation, cardiac rupture, and eventually progressive HF. Nonischemic dilated cardiomyopathy (DCM), characterized by a progressive left ventricular (LV) chamber dilatation and global myocardial dysfunction, represents the most frequent subtype of non-ICM. However, the mechanism of DCM remains elusive and novel pharmacologic approaches to treat DCM scarce ([@B1]).

With the advances in recent technologies applied to medical diagnosis and treatment, new possibilities have emerged to understand the pathophysiology of many diseases. Recently, it is reported that noncoding RNAs, especially microRNAs (miRNAs), long noncoding RNAs (lncRNA), and circular RNAs, serve as epigenetic regulators of cardiac gene expression and thus significantly influence cardiac homeostasis and functions ([@B6]). lncRNA, as a subclass of noncoding RNAs with a length of more than 200 nt and no open reading frame are profoundly involved in multiple cardiovascular diseases ([@B4]). A large-scale case−control association study identified the lncRNA MI-associated transcript as a risk allele for MI in Japanese subjects ([@B21]). Recent report showed the association of polymorphisms in long noncoding RNA H19 with coronary artery disease risk in a Chinese population ([@B12]). Moreover, many results revealed the correlation of H19 expression with tumors ([@B34]), vascular injury ([@B25]), atherosclerotic plaques ([@B17]), and high blood pressure ([@B48]).

Results from RNA deep sequencing revealed distinguished lncRNAs expression signature, but not messenger RNAs (mRNAs) or miRNAs in human LV between ischemic and nonischemic failing hearts, suggesting that lncRNA expression profiles are more sensitive to different HF etiologies than mRNA or miRNA expression ([@B54]). In addition, patients subjected to MI showed distinct lncRNAs expressions in blood cells from the control ([@B49]). Recent report found that lncRNA LIPCAR should be a novel biomarker of cardiac remodeling and to predict future death in patients with HF ([@B27]). Although latest reports have collectively described the vital roles of lncRNAs in cardiovascular biology and diseases, questions that whether they can be used as biomarkers to discriminate the etiology or determine the efficacy of therapy of HF still exist.

In the present study, we compared the lncRNAs expression pattern through RNA microarray and performed multiple analyses to identify the possible functions and pathways of the differential expressed lncRNAs in plasma of patients with DCM and ICM. These results provided some important evidences which may help to conveniently identify the etiology involved in the reverse remodeling of heart with DCM or ICM, and possibly to dynamically determine the efficacy of therapy, and explore a better future prognosis evaluation.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2_1}
----------------

The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki. The Ethics Committee of Shanghai East Hospital, Tongji University School of Medicine approved the protocol of this study(Num: ECSEH2016-037) and all enrolled patients gave the written informed consent.

Study Population and Blood Collection {#s2_2}
-------------------------------------

Twenty peripheral fasting blood samples were donated by CHF patients with DCM (n = 11) and ICM (n = 9). Plasmas were analyzed by RNA microarray (Arraystar Human lncRNA microarray, v4.0, containing 40,173 lncRNAs and 20,730 coding transcripts). Inclusion criteria were as follows: (1) All patients had ventricular dilation and LV ejection fraction \< 50%. (2) Patients with ICM were diagnosed by coronary angiogram or suffered from MI before. (3) All patients with DCM were proved nonischemic by coronary angiogram or coronary computed tomography angiography and in the absence of hypertensive, valvular, or congenital heart diseases. Patients with the following conditions were excluded from the study: (1) Cardiac resynchronization/modulation therapy in 3 months, (2) acute MI in 3 months, (3) coronary artery bypass grafting in 3 months, (4) malignant tumor or immune diseases were excluded.

Peripheral blood was collected in Vacutainer plastic blood collection tubes with spray-coated K2EDTA (Kehua Bio-Engineering co., catalog \# 25022101, Shanghai, China). Plasma samples were collected within 4 h according to standard procedures and frozen at −80°C prior to the RNA extraction.

Echocardiograms were done with (Philips, IE33 Ultrasound, Netherlands). Pro-Brain Natriuretic Peptide were measured by Electrochemical Luminescence Automatic Immunoassay System(Roche, Cobas E411, Swiss).

lncRNA and mRNA Microarray Experiment {#s2_3}
-------------------------------------

Total RNA was prepared with TRIzol Reagent (Thermo Fisher Scientific, catalog \# 15596026, Waltham, MA, USA) in according to the manufacturer's instructions. The quality and quantity of extracted RNA were assessed by the NanoDrop ND1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) ([**Table S1**](#SM1){ref-type="supplementary-material"}). RNA samples were labeled by Quick Amp Labeling Kit (Agilent, catalog \# 5190-0442, Palo Alto, CA, USA), and purified by RNeasy Mini Kit (Qiagen, catalog \# 74104, Dusseldorf, German). The microarray hybridization were performed using Agilent Gene Expression Hybridization Kit (Agilent, catalog \# 5188-5242, Palo Alto, CA, USA). After washing, the hybridized arrays were scanned by Agilent DNA microarray Scanner (Agilent, G2505C, Palo Alto, CA, USA) and finally were analyzed by Agilent Feature Extraction software (Agilent, version 10.5.1.1, Palo Alto, CA, USA). The differentially expressed transcripts were identified by fold-change screening at a threshold more than two-fold and a *p*-value \< 0.05.

KEGG and GO Pathway Analysis {#s2_4}
----------------------------

Statistical enrichment was evaluated by Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) pathway analysis. To explore the significant pathways of the differentially expressed genes in the KEGG database (<http://www.genome.jp/kegg>), pathway analysis was performed using DAVID software (<https://david.ncifcrf.gov/>). GO enrichment of the target genes was performed to elucidate the biological roles including molecular function, biological process, and cellular component aspects of the differentially expressed genes by the GOseq R package (<http://www.geneontology.org>) and corrected by *p*-value (*p* \< 0.05 were considered significantly enriched).

Chromosome Distribution of Differentially Expressed lncRNAs {#s2_5}
-----------------------------------------------------------

According to the microarray analysis results in which 3,222 differentially expressed lncRNAs between DCM and ICM group were identified and their locations information provided in chromosomes. All the chromosome distribution of these lncRNAs were analyzed and presented in the histogram.

Quantitative Real-Time PCR {#s2_6}
--------------------------

lncRNA microarray data were validated using quantitative real-time PCR (qRT-PCR). SuperScript III Reverse Transcriptase (Thermo Fisher Scientific, catalog \# 18080044, Waltham MA, USA) was used in accordance with the manufacturer's instructions. qRT-PCR was performed using the Applied Biosystems ViiA 7 Real-Time PCR System (Thermo Fisher Scientific, Waltham MA, USA) and 2\*PCR Master Mix (Arraystar Inc., catalog \# AS-MR-006-5, Rockville, MD, USA). Primers were designed online using Primer 5 software and evaluated by the Basic Local Alignment Search Tool at the National Center for Biotechnology Information ([**Table 1**](#T1){ref-type="table"}). Cycle threshold (Ct) values were used to quantify the expression levels of genes as 2^−ΔΔCT^ according to previous report ([@B31]). β-Actin was applied as a normalization control ([@B36]).

###### 

Primers designed for quantitative real-time PCR (qRT-PCR) validation of candidate long noncoding RNAs (lncRNAs).

  -----------------------------------------------------------------------------------
  Name              Primers                           Tm (°C)   Product length (bp)
  ----------------- --------------------------------- --------- ---------------------
  ENST00000554552   F:5′ CAGAAGAAGGCAAGTCTCAATG 3′\   60        159
                    R:5′ GAACAGTCCCAGAAAGATAGCA 3′              

  ENST00000494340   F:5′ CCAAAGTCCAGCTACCACAATA 3′\   60        172
                    R:5′ TCCCGTGACCATAGGAAGATA 3′               

  NR_046647         F:5′ CAGGTCTACAGAGCAATGGTG 3′\    60        77
                    R:5′ GCAAATTGAGTCTTCTGTTTTG 3′              

  NR_109994         F:5′ GCCAGATAAGAATAGCTCCAGT 3′\   60        163
                    R:5′ TAGCAGTGAGCAAGACTCCATA 3′              

  NR_029376         F:5′ CCAACCCGATACTATACACGAC 3′\   60        72
                    R:5′ GGTCTTACCGTTGCTGCTTAT 3′               

  T109935           F:5′ TTGCCGATGTGGAGTGATT 3′\      60        156
                    R:5′ TTGTCTGGTCCTTTGCTTGA 3′                

  T023556           F:5′ CGTATGCCCCTAGTCCTGTT 3′\     60        182
                    R:5′ CACGGAAGTTGAGTCTGTGGTT 3′              

  T201134           F:5′ ACTGGAACTACGGAAATGACG 3′\    60        102
                    R:5′ GATGTTGCGAGTTGTCTTCAC 3′               

  T226011           F:5′ TCCAATCAACCGCCTTCTC 3′\      60        257
                    R:5′ TAACCCTATGGCCCTCCTT 3′                 

  T207073           F:5′ GGCATTTCTTTAGCTGTTGC 3′\     60        192
                    R:5′ TCTTCTTTATGGAGGAGGTGAC 3′              

  T191270           F:5′ ACGGCTAAAATCCAAAGGC 3′\      60        111
                    R:5′ TGACACGACGACAGAAACATC 3′               

  uc004bsl.1        F:5′ AGAGCAGTATGTGGCACCTTT 3′\    60        178
                    R:5′ ACCCGCACATCCATGTAGTA 3′                

  β-actin(H)        F:5′ GTGGCCGAGGACTTTGATTG 3′\     60        73
                    R:5′ CCTGTAACAACGCATCTCATATT 3′             
  -----------------------------------------------------------------------------------

Coding--Noncoding Gene Coexpression Network {#s2_7}
-------------------------------------------

The coding--noncoding gene coexpression network was constructed based on the correlation analysis between the differentially expressed lncRNAs and mRNAs. The algorithm has been previously described ([@B29]). The Pearson correlation coefficient between lncRNAs and coding genes was calculated based on the selected lncRNAs and mRNAs expression levels. The parameter is Pearson correlation coefficient (abs) ≥ 0.8, p-value ≤ 0.05, and FDR ≤ 0.05. The coexpression network was illustrated by Cytoscape (v2.8.3) (Institute of Systems Biology, Seattle, US).

Statistics {#s2_8}
----------

Data are presented as mean ± standard error of the mean (SEM) and were analyzed by the statistics software SPSS (SPSS Inc, version 22.0, Chicago, IL, USA). Two-tail Student's t-test was used to calculate the differences between DCM and ICM group. p-value of \<0.05 were regarded as statistically significant. The association between lncRNAs and clinical data was assessed using the Pearson correlation coefficient.

Results {#s3}
=======

Baselines Characteristics {#s3_1}
-------------------------

A total of 20 individuals who participated in the study were diagnosed with ICM (n = 9) or DCM (n = 11) at hospital. Baseline characteristics of study population are shown in [**Table 2**](#T2){ref-type="table"}. In this study, patients were predominantly men (age 59.80 ± 12.81 years) accounting for 90% (18/20). Sixty-five percent patients suffered from hypertension and 25% from diabetes. Patients with DCM showed a lower EF (p \< 0.005) and higher left ventricular end diastolic diameter (LVEDD) (p \< 0.000) and left ventricular end systolic dimension (LVESD) (p \< 0.000) than those with ICM. [**Figure S1**](#SM1){ref-type="supplementary-material"} presents the representative echocardiograms of DCM and ICM patients. The mean values of pro-Brain Natriuretic Peptide were 4,755.05 ± 5,432.78 ng/l. Most patients received recommended pharmacological therapy for CHF (beta-blockers, 95%; angiotensin-converting enzyme inhibitors or angiotensin receptor blocker, 60%; diuretics, 70%).

###### 

Demographic and clinical characteristics of the study population.

                         Overall (N = 20)      ICM (N = 9)           DCM (N = 11)          *p* value
  ---------------------- --------------------- --------------------- --------------------- ---------------
  Age (years)            59.80 ± 12.81         62.33 ± 8.26          57.73 ± 15.70         0.439
  Male *n* (%)           18 (90.0)             8 (88.9)              10(90.9)              0.881
  Hypertension *n* (%)   13 (65)               5 (55.6)              8 (72.7)              0.423
  Diabetes *n* (%)       5 (25)                3 (33.3)              2 (18.2)              0.436
  NYHA                                                                                     
  II                     9 (45.0)              4 (44.4)              5 (45.4)              
  III                    8 (40.0)              4 (44.4)              4 (36.4)              
  IV                     3 (15.0)              1 (11.2)              2 (18.2)              
  Systolic BP (mmHg)     119.20 ± 19.60        119.00 ± 20.89        119.36 ± 19.51        0.968
  Diastolic BP (mmHg)    69.95 ± 9.94          71.78 ± 9.431         68.45 ± 10.55         0.472
  Heart rate (per min)   77.50 ± 14.61         79.44 ± 17.01         75.91 ± 12.95         0.604
  LVEF (%)               33.10 ± 6.45          37.44 ± 4.64          29.55 ± 5.56          **0.003\*\***
  LVEDD (mm)             68.60 ± 11.37         59.22 ± 3.31          76.27 ± 9.63          **0.000\*\***
  LVESD (mm)             58.00 ± 11.63         48.22 ± 3.15          66.00 ± 9.61          **0.000\*\***
  NT-proBNP (ng/l)       4,755.05 ± 5,432.78   5,505.11 ± 7,707.28   4,141.36 ± 2,763.38   0.590
  Medication                                                                               
  β-Blockers *n* (%)     19(95.0)              8 (88.9)              11 (100.0)            0.257
  ACEI or ARB *n* (%)    12(60.0)              4 (44.4)              8 (72.7)              0.199
  Diuretics *n* (%)      14(70.0)              6 (66.7)              8 (72.7)              0.769

Values are mean with SD (±) or absolute numbers with relative frequencies (%) at the time of study enrolment. LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; LEVSD, left ventricular end diastolic diameter pro; ACEI, inhibitors of angiotensin converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association. \*\*p \< 0.01.

lncRNA and mRNA Expression Profiles in DCM and ICM {#s3_2}
--------------------------------------------------

Arraystar Human lncRNA microarray was used to investigate the lncRNA and mRNA expression changes in plasma of patients with DCM and ICM. We identified 3,222 lncRNAs that were significantly dysregulated in DCM patients vs. ICM patients \[fold change (FC) ≥ 2.0, p \< 0.05\] with 1,637 upregulated and 1,585 downregulated. The top 20 most significant up- and downregulated lncRNAs were shown in [**Tables S2**](#SM1){ref-type="supplementary-material"} and [**S3**](#SM1){ref-type="supplementary-material"}.

Among these lncRNAs transcripts, T342171 was the most upregulated one with an FC of 231.48611, while ENST00000445280 was the most downregulated lncRNA with an FC of 66.66290. The lncRNA and mRNA expression variation between DCM and ICM were shown in a heat map ([**Figure 1A**](#f1){ref-type="fig"}) and the clustering analysis in different groups was presented with the volcano plots and the scatter plots ([**Figures 2A, C**](#f2){ref-type="fig"}).

![The heat map and hierarchical clustering analysis of long noncoding RNAs (lncRNAs) **(A)** and messenger RNAs (mRNAs) **(B)** that were differentially expressed between the peripheral plasma samples from dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) patients. Top 20 upregulated and top 20 downregulated results were filtered with fold change (FC) ≥ 2.0 and p 0.05. Expression values are represented in shades of red and green, indicating expression above and below the relative expression respectively. −3.0, 0, and 3.0 are FCs in the corresponding spectrum. The magnitude of deviation from the median is represented by the color saturation.](fgene-10-01116-g001){#f1}

![The volcano plots and scatter plots of long noncoding RNA (lncRNA) **(A, C)** and messenger RNA (mRNA) **(B, D)** expression variation between the dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) patients. Expression values of 11,784 lncRNA and 7,473 mRNA in DCM and ICM patients were converted to log~2~ (fold change) and were compared to −log~10~ (p-value) using a volcano plot. A threshold of p 0.05 and fold change ≥2.0 (The red dots represented upregulated, the green dots represented downregulated). Scatter plots indicated the normalized signal values of the plasma sample (log~2~ scaled).The red dots represented upregulation and fold change ≥ 2.0, the green dots represented downregulation and fold change ≥ 2.0.](fgene-10-01116-g002){#f2}

Additionally, we identified 1,911 significantly differentially expressed mRNAs in which 911 were upregulated, while 1,000 were downregulated (FC ≥ 2.0, p \< 0.05) in DCM patients compared with ICM patients. The top 20 significant up- and downregulated mRNAs are showed in [**Tables S4**](#SM1){ref-type="supplementary-material"} and [**S5**](#SM1){ref-type="supplementary-material"}. The most upregulated mRNA transcript was FUK (NM_145059), with an FC of 216.16425 while the most downregulated was SLC6A1 (NM_003042), with an FC of 18.49104. The heat map was shown in [**Figure 1B**](#f1){ref-type="fig"}. The variation of mRNA transcripts expression between DCM and ICM group was presented with the volcano plots and the scatter plots ([**Figures 2B, D**](#f2){ref-type="fig"}).

Chromosome Distribution of Differentially Expressed lncRNAs in DCM and ICM Group {#s3_3}
--------------------------------------------------------------------------------

Next, we evaluated the chromosome distribution of lncRNAs differentially expressed in plasma between patients with DCM and ICM. As shown by [**Figure 3**](#f3){ref-type="fig"}, large amount of differentially expressed lncRNAs were located in chromosome 1 (265 lncRNA) and 2 (264 lncRNA) while only one lncRNA named uc022bqs.1 is in mitochondrial genome.

![Chromosome distribution of long noncoding RNAs (lncRNAs) differentially expressed in plasma between the DCM and ICM patients. chr, chromosome; M, mitochondrial.](fgene-10-01116-g003){#f3}

Gene Ontology and KEGG Pathway Enrichment Analysis {#s3_4}
--------------------------------------------------

To investigate the biological functions of lncRNAs in plasma of HF patients with distinct etiology, we performed a functional enrichment analysis of the mRNAs coexpressed with each of the differentially expressed lncRNAs. The enriched functional terms were used as the predicted terms for each given lncRNA. [**Figures 4A, B**](#f4){ref-type="fig"} showed the top 10 upregulated and downregulated GO terms respectively for the differences in mRNAs coexpressed with lncRNAs in DCM and ICM patients. The most enriched upregulated functional terms included positive regulation of I-kappaB kinase/nuclear factor (NF)-kappaB signaling (GO:0043123), regulation of cellular localization (GO:0060341), and inorganic ion homeostasis (GO:0098771)([**Figure 4A**](#f4){ref-type="fig"}). [**Figure 4B**](#f4){ref-type="fig"} showed the top 10 downregulated genes GO analysis which consist of acid secretion (GO:0046717) and myosin heavy chain binding (GO:0032036).

![Top 20 GO terms for the differences in coexpressed long noncoding RNA (lncRNA) genes in the dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) patients. The top 10 Gene Ontology (GO) terms that upregulated genes correlated with **(A)**. The top 10 GO terms that downregulated genes correlated with **(B)**. The bar plot shows the top 10 enrichment score \[−log10(p-value)\] value of the significant enrichment GO terms.](fgene-10-01116-g004){#f4}

Furthermore, the KEGG pathway analysis revealed that the upregulated mRNAs coexpressed with lncRNAs were mainly enriched in natural killer cell mediated cytotoxicity, autoimmune thyroid disease and porphyrin and chlorophyll metabolism. While the downregulated terms were primarily involved in the regulation of ras signaling pathway, sphingolipid signaling pathway and glycosaminoglycan degradation ([**Figure 5**](#f5){ref-type="fig"}). The top 20 KEGG pathways are listed in [**Figure 5**](#f5){ref-type="fig"}.

![Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis. Top 20 pathways for the differences in long noncoding RNA (lncRNA) genes coexpressed in the dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) patients. The red bars are associated with upregulated pathways, the green bars are associated with downregulated pathways. The bar plot shows the top 20 enrichment score \[−log10(p-value)\] value of the significant enrichment gene ontology terms.](fgene-10-01116-g005){#f5}

Validation of the Microarray Data by Quantitative Real-Time PCR {#s3_5}
---------------------------------------------------------------

To validate the lncRNAs expression alterations detected by microarray, a total of 12 differentially expressed lncRNAs (T226011, ENST00000554552, T201134, T023556, T109935, NR_109994, NR_046647, NR_029376, ENST00000494340, T191270, T207073, uc004bsl.1) were selected and their expressions examined by RT-PCR. Consistent with the microarray chip data, there were more than five fold increase of ENST00000554552 and T226011 in DCM group compared with the ICM group ([**Figures 6A, B**](#f6){ref-type="fig"}). Meanwhile, circulating NR_109994, T023556, T201134, NR_029376, T109935, and NR_046647 increased 3.34-fold, 3.34-fold, 2.95-fold, 2.76-fold, 2.19-fold, and 1.23-fold respectively in DCM group compared with ICM ([**Figures 6C--H**](#f6){ref-type="fig"}). Other four lncRNAs showed no significant differences between the two groups ([**Figures 6I--L**](#f6){ref-type="fig"}).

![Validation of the differential expression of long noncoding RNAs (lncRNAs) by quantitative real-time PCR (qRT-PCR) (A--L). Levels of the lncRNA (T226011, ENST00000554552, T201134, T023556, T109935, NR_109994, NR_046647, NR_029376, ENST00000494340, T191270, T207073, uc004bsl.1) in plasma of patients with dilated cardiomyopathy (DCM) or ischemic cardiomyopathy (ICM). DCM group, n = 11; ICM group, n = 9. \*p 0.05 versus control, \*\*p 0.01 versus control.](fgene-10-01116-g006){#f6}

lncRNA--mRNA Network Analysis {#s3_6}
-----------------------------

To further elucidate the relevant functions of the target genes, a functional network was constructed based on the GO analysis using Cytoscape. 7 validated differentially expressed lncRNA in DCM group compared with ICM group were used to construct a coding--noncoding gene coexpression network. [**Figure 7**](#f7){ref-type="fig"} showed the network profiles based on these 7 lncRNAs and 906 mRNAs. Our results showed that one lncRNA may correlate with 7--517 mRNAs. lncRNA T023556 is correlated with 517 mRNAs in which 227 upregulated and 290 downregulated. lncRNA T201134 is correlated with 401 mRNAs with 161 upregulated and 240 downregulated. Total of 203 mRNAs, including 103 upregulated and 100 downregulated mRNAs are predicted to correlate with lncRNA T226011. As shown by [**Figure 7**](#f7){ref-type="fig"}, lncRNA T109935 and NR_046647 were correlated with eight and seven mRNAs respectively.

![Coding--noncoding gene coexpression networks network of the seven validated long noncoding RNAs (lncRNAs) and their correlated messenger RNAs (mRNAs). The network represents coexpression correlations between seven lncRNAs and their correlated mRNAs. Red nodes represent lncRNAs. Blue nodes represent correlated mRNAs. The real lines between lncRNAs and mRNAs mean positive correlation, while the dotted lines mean negative correlation.](fgene-10-01116-g007){#f7}

Associations Between Upregulated lncRNAs and the Clinical Index {#s3_7}
---------------------------------------------------------------

The relationship between the rising lncRNAs and the clinical index were also studied using Pearson linear correlation analysis. We choose three upregulated lncRNAs including ENST00000554552,T226011 and NR_109994. Pearson linear correlation coefficient showed that there were no significant correlations between EF, pro-Brain Natriuretic Peptide, and these lncRNAs (p \> 0.05). There were moderate positive correlations between LVEDD, LVESD, and lncRNAs (0.4 \< r \< 0.6, p \< 0.05) ([**Table 3**](#T3){ref-type="table"}).

###### 

Correlations between three long noncoding RNAs (lncRNAs) and the clinical data including EF, LVEDD, LVESD, and NT-proBNP by Pearson linear correlation analysis.

                    EF       LVEDD   LVESD   NT-proBNP                                
  ----------------- -------- ------- ------- ----------- ------- ----------- -------- -------
  ENST00000554552   −0.210   0.203   0.487   0.003\*\*   0.489   0.003\*\*   0.076    0.649
  T226011           −0.286   0.084   0.593   0.000\*\*   0.575   0.000\*\*   −0.018   0.916
  NR_109994         −0.200   0.227   0.550   0.001\*\*   0.468   0.004\*\*   0.111    0.506

\*\*p \< 0.01.

Discussion {#s4}
==========

The present findings revealed for the first time the specific expression pattern of both protein-coding and lncRNAs in plasma of HF patients due to DCM and ICM, confirming that new biomarkers could be reliably identified using microarray-based approaches. As previously reported, transcriptional profiling has been utilized extensively in human HF to explore the new pathways involved in the complex disease ([@B18]), to identify novel biomarkers for better diagnostic and prognostic accuracy ([@B26]), and to evaluate the treatment responses of different medications or implanted devices ([@B32]; [@B33]; [@B40]). Results from animal diseases models demonstrated the vital roles of lncRNAs in cardiac hypertrophy ([@B19]; [@B52]), MI ([@B21]; [@B38]), coronary artery disease ([@B12]), vascular injury ([@B25]), atherosclerotic plaques ([@B17]), and high blood pressure ([@B48]). Recently, RNAseq was used to determine the lncRNAs expression in human hearts ([@B54]; [@B44]; [@B46]). The lncRNA expression landscape could distinguish cardiomyopathic samples before and after treatment ([@B54]; [@B44]) and specific lncRNA profile was found in hearts from HF patients with DCM and restrictive cardiomyopathy ([@B46]). Recent microarray analysis demonstrated the lncRNA dysregulation in hearts suffered from ischemic HF compared to control hearts ([@B15]), as well as in hearts with DCM from control ([@B30]). Therefore, lncRNAs are closely involved in the cardiac pathophysiological processes. We presented the specific expression pattern of both mRNAs and lncRNAs in plasma of HF patients subjected to DCM and ICM, supporting the notion that new lncRNAs biomarkers in plasma may be applied to discriminate the etiology of HF from DCM and ICM.

Further results showed positive relationships in lncRNA expressions between tissues and plasmas in patients with hepatocellular carcinoma ([@B51]) and colorectal cancer ([@B35]). Compared to the tissues, isolation of nucleic acids from plasma serves as an ideal method for early and differentiation diagnosis, evaluation the medication responses, and assessment of the prognosis. It is reported that specific lncRNAs, aberrantly expressed in the plasma of pregnant women with typical fetal congenital heart defects, may be used as novel biomarkers for prenatal diagnosis of fetal CHD ([@B16]). Circulating lncRNAs could also be used as biomarkers of LV diastolic function and remodeling in patients with well-controlled type 2 diabetes ([@B5]) or to predicts survival in patients with HF ([@B27]). Therefore, lncRNA expression in the plasma may serve as convenient and novel diagnostic markers in heart diseases. The present study showed a signature lncRNA profile in plasma of patients with DCM and ICM. In addition, several differentially expressed lncRNAs were chosen for qRT-PCR validation, and the results were consistent with the microarray analysis findings. The moderate positive correlations between LVEDD, LVESD and some upregulated lncRNAs also suggested the associations between lncRNAs and chronic cardiac enlargement. Recently, Zhang et al. investigated the specific circulating lncRNAs in patients with DCM compared to that of the control ([@B55]). They found both levels of circulating lncRNA ENST00000507296 and ENST00000532365 were significantly correlated with the cardiac function. In this study, circulating lncRNA ENST00000507296 level was also upregulated in DCM group compared to ICM group, suggesting the role of this lncRNA in DCM compared to ICM. How these molecules are involved in the onset or progress of cardiac dysfunction are still elusive. Due to the variability in etiologies, presentations of diseases and treatment strategies, convenient markers for differential diagnosis is of great importance in clinical settings. Our data indicated that different panel or expression signature of lncRNA may serve as a good diagnostic marker for making a distinction of HF patients due to DCM from ICM.

Previous report ([@B27]) showed that most of the lncRNAs that originate from mitochondrial genome were downregulated in plasma of patients with high LV remodeling 12 months after MI and the strongest association were found between downregulation of uc022bqs.1 and severe LV remodeling. We found that uc022bqs.1 expression is decreased in DCM compared to ICM. Therefore, downregulation of uc022bqs.1 may partly explain the much higher LVEDD and LVESD in DCM than ICM, indicating a more sever remodeling in DCM than the ICM. We also found large amount of differentially expressed lncRNAs in other chromosomes especially chromosome1 and 2, how are these lncRNAs involved in the progress of HF with different etiologies need further exploration.

lncRNAs were reported to play crucial roles in regulating gene expression, transcription, posttranscription, and epigenetic modification ([@B3]). Our GO and KEGG pathway analyses predicted the potential functions of the differentially expressed lncRNAs identified in this study. GO analysis revealed that these lncRNAs are profoundly involved in multiple biological processes including upregulated functional terms associated with acid secretion, lung epithelial cell differentiation and lung cells differentiation, and downregulated positive regulation of I-kappaB kinase/NF-kappa B signaling, regulation of cellular localization, and inorganic ion homeostasis. Compelling evidences demonstrated the role of NF-kappa B signaling in the regulation of immune cell maturation and inflammation ([@B2]; [@B20]; [@B13]), and acute hypoxia and reperfusion injury ([@B41]; [@B56]). Prolonged activation of NF-kappa B was proved to promote HF by triggering chronic inflammation signals and enhanced endoplasmic reticulum stress responses and cell death ([@B37]; [@B23]; [@B24]; [@B14]). Many reports confirmed the critical role of inflammation in ventricular remodeling and final HF post MI ([@B53]). The present results suggested that inflammation triggered by NF-kappa B signaling may dominate in ICM other than DCM. In addition, increased myosin heavy chain binding and ATP utilization lead to the hypercontractile sarcomere in hypertrophic cardiomyopathy ([@B42]; [@B39]). In our molecular function analysis results, myosin heavy chain binding was upregulated in DCM group compared to ICM, suggesting more profound involvement of lncRNA molecules associated with this pathway in DCM from ICM.

The KEGG pathway analysis revealed that the upregulated mRNAs coexpressed with lncRNAs were mainly enriched in natural killer cell mediated cytotoxicity, while the downregulated terms in ras signaling pathway and sphingolipid signaling pathway. Among these, natural killer cell mediated cytotoxicity was reported to decrease in advanced HF patients ([@B50]; [@B7]). The present result showed mRNAs coexpressed with lncRNAs associated with natural killer cell mediated cytotoxicity downregulated in ICM plasma compared to DCM group. Sphingolipids was reported to contribute to pathophysiological mechanisms by modifying signaling and metabolic pathways ([@B43]). Recent findings demonstrated its involvement in cardiovascular diseases ([@B10]; [@B45]), and diabetes ([@B22]). Data from animal experiment underlined a cardioprotective function of S1P signaling in ischemia reperfusion injury ([@B47]). Our results further showed that the expression of mRNAs coexpressed with lncRNAs associated with sphingolipid signaling pathway in plasma may differ HF patients with DCM from ICM. Further studies are needed to explore how other dysregulated mRNAs coexpressed with lncRNAs enriched signaling pathways contribute to the progression of HF.

Many studies demonstrated that lncRNAs act as a potentially new and crucial regulators in gene expression, transcription, posttranscription, and epigenetics levels ([@B3]). Among these, modulation of mRNA represents one of the most important actions of lncRNA in diseases. Our coexpression network analysis of the seven validated lncRNA and their correlated mRNAs showed that lncRNAs may regulate several to hundreds of mRNAs. Recent study revealed that some lncRNAs with the central topological features were found in the HF-related lncRNA--mRNA network ([@B8]). The coexpression network indicates that the interregulation of lncRNAs and mRNAs is involved in the pathophysiology of HF and warrants further investigations.

In conclusion, the present study revealed a specific expression pattern of both protein-coding and lncRNAs in plasma of HF patients with DCM and ICM. Moreover, the differentially expressed lncRNAs are involved in several specific biological processes, molecular functions and cellular components and regulate some signaling pathways which may uncover the different mechanisms in which HF is attributed. Therefore, these findings may lead to new insights into the novel diagnostic and therapeutic targets for HF patients with DCM and ICM.
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